# A Phase 1/2 Study to Investigate CRB-701 in Solid Tumors

> **NCT06265727** · PHASE1,PHASE2 · RECRUITING · sponsor: **Corbus Pharmaceuticals Inc.** · enrollment: 348 (estimated)

## Conditions studied

- Solid Tumor, Adult

## Interventions

- **DRUG:** CRB-701
- **DRUG:** Anti-PD-1

## Key facts

- **NCT ID:** NCT06265727
- **Lead sponsor:** Corbus Pharmaceuticals Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-04-01
- **Primary completion:** 2027-01-16
- **Final completion:** 2027-01-27
- **Target enrollment:** 348 (ESTIMATED)
- **Last updated:** 2026-01-08

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06265727

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06265727, "A Phase 1/2 Study to Investigate CRB-701 in Solid Tumors". Retrieved via AI Analytics 2026-07-08 from https://api.ai-analytics.org/clinical/NCT06265727. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*